Unintentional fetal exposure to natalizumab appeared unconnected to lower mean gestational age, lower mean birth weight or shorter mean birth length in women with multiple sclerosis, according to studies presented at the American Academy of Neurology annual meeting. Kerstin Hellwig of Ruhr University said "accidental exposure to natalizumab in the first trimester does not appear to cause major risk to the children."

Related Summaries